{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:31:43Z","timestamp":1778092303922,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This subgroup analysis of the Cancer-VTE Registry, a nationwide, large-scale, multicenter observational study with a 1-year follow-up, assessed real-world data on venous thromboembolism (VTE) among Japanese patients with breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with stage II\u2013IV pretreatment breast cancer screened for VTE at enrollment were included. During the 1-year follow-up period, incidences of VTE, bleeding, and all-cause death, and background factors associated with VTE risk were examined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 9,630 patients in the Cancer-VTE Registry analysis set, 993 (10.3%) had breast cancer (973 [98.0%] did not have and 20 [2.0%] had VTE at baseline). The mean age was 58.4\u00a0years, 73.4% of patients had stage II cancer, and 94.8% had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0. Risk factors for VTE at baseline by univariable analysis were age\u2009\u2265\u200965\u00a0years, ECOG PS of 2, VTE history, and D-dimer\u2009&gt;\u20091.2\u00a0\u03bcg\/mL. During follow-up, the incidence of symptomatic VTE was 0.4%; incidental VTE requiring treatment, 0.1%; composite VTE (symptomatic VTE and incidental VTE requiring treatment), 0.5%; bleeding, 0.2%; cerebral infarction\/transient ischemic attack\/systemic embolic event, 0.2%; and all-cause death, 2.1%. One patient with symptomatic VTE developed pulmonary embolism (PE) and died. Incidences of VTE and all-cause death were higher in patients with VTE vs without VTE at baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In Japanese patients with breast cancer, VTE screening before initiating cancer treatment revealed a 2.0% prevalence of VTE. During follow-up, one patient had a fatal outcome due to PE, but the incidences of VTE were low.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration<\/jats:title>\n                <jats:p>UMIN000024942; UMIN Clinical Trials Registry: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.umin.ac.jp\/ctr\/\">https:\/\/www.umin.ac.jp\/ctr\/<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12282-023-01452-7","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T18:02:10Z","timestamp":1681754530000},"page":"607-616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry"],"prefix":"10.1007","volume":"30","author":[{"given":"Shozo","family":"Ohsumi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyuki","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari S.","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"1452_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1452_CR2","first-page":"45","volume":"120","author":"DM Parkin","year":"1992","unstructured":"Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ. 1992;120:45\u2013173.","journal-title":"IARC Sci Publ"},{"key":"1452_CR3","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/jjco\/hyaa112","volume":"50","author":"Y Ohashi","year":"2020","unstructured":"Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry. Jpn J Clin Oncol. 2020;50:1246\u201353 (Erratum in: Jpn J Clin Oncol 2020;50:1346).","journal-title":"Jpn J Clin Oncol"},{"key":"1452_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/jth.14630","volume":"18","author":"L Gervaso","year":"2020","unstructured":"Gervaso L, Montero AJ, Jia X, Khorana AA. Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. J Thromb Haemost. 2020;18:162\u20138.","journal-title":"J Thromb Haemost"},{"key":"1452_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-020-05783-3","volume":"183","author":"KZ Thein","year":"2020","unstructured":"Thein KZ, Htut TW, Ball S, Swarup S, Sultan A, Oo TH. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4\/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2020;183:479\u201387.","journal-title":"Breast Cancer Res Treat"},{"key":"1452_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1182\/blood-2015-01-625582","volume":"127","author":"AJ Walker","year":"2016","unstructured":"Walker AJ, West J, Card TR, Crooks C, Kirwan CC, Grainge MJ. When are breast cancer patients at the highest risk of venous thromboembolism? A cohort study using English health care data. Blood. 2016;127:849\u201357 (quiz 953).","journal-title":"Blood"},{"key":"1452_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/2292550320967397","volume":"29","author":"M Castaldi","year":"2021","unstructured":"Castaldi M, George G, Stoller C, Parsikia A, McNelis J. Independent predictors of venous thromboembolism in patients undergoing reconstructive breast cancer surgery. Plast Surg (Oakv). 2021;29:160\u20138.","journal-title":"Plast Surg (Oakv)"},{"key":"1452_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001275","volume":"9","author":"F Horsted","year":"2012","unstructured":"Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9: e1001275.","journal-title":"PLoS Med"},{"key":"1452_CR9","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","volume":"49","author":"AJ Walker","year":"2013","unstructured":"Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer\u2014a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49:1404\u201313.","journal-title":"Eur J Cancer"},{"key":"1452_CR10","unstructured":"National Cancer Center Japan. Cancer statistics. 2022. https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/14_breast.html. Accessed 23 July 2022."},{"key":"1452_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/cncr.30364","volume":"123","author":"JS Brand","year":"2017","unstructured":"Brand JS, Hedayati E, Bhoo-Pathy N, Bergh J, Hall P, Humphreys K, et al. Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: a population-based cohort study. Cancer. 2017;123:468\u201375.","journal-title":"Cancer"},{"key":"1452_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.critrevonc.2017.03.006","volume":"113","author":"JB Guy","year":"2017","unstructured":"Guy JB, Bertoletti L, Magn\u00e9 N, Rancoule C, Mah\u00e9 I, Font C, et al. Venous thromboembolism in radiation therapy cancer patients: findings from the RIETE registry. Crit Rev Oncol Hematol. 2017;113:83\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1452_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.thromres.2018.11.012","volume":"173","author":"M Li","year":"2019","unstructured":"Li M, Guo Q, Hu W. Incidence, risk factors, and outcomes of venous thromboembolism after oncologic surgery: a systematic review and meta-analysis. Thromb Res. 2019;173:48\u201356.","journal-title":"Thromb Res"},{"key":"1452_CR14","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/cam4.4559","volume":"11","author":"E Daguenet","year":"2022","unstructured":"Daguenet E, Maison M, Tinquaut F, Giroux EA, Bertoletti L, Suchaud JP, et al. Venous thromboembolism and radiation therapy: the final radiation-induced thrombosis study analysis. Cancer Med. 2022;11:1753\u201362.","journal-title":"Cancer Med"},{"key":"1452_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1160\/TH16-08-0615","volume":"117","author":"C Ay","year":"2017","unstructured":"Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost. 2017;117:219\u201330.","journal-title":"Thromb Haemost"},{"key":"1452_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.thromres.2011.11.025","volume":"130","author":"AA Onitilo","year":"2012","unstructured":"Onitilo AA, Doi SA, Engel JM, Glurich I, Johnson J, Berg R. Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience. Thromb Res. 2012;130:27\u201331.","journal-title":"Thromb Res"},{"key":"1452_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018910","volume":"8","author":"Y Ohashi","year":"2018","unstructured":"Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, et al. Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry). BMJ Open. 2018;8: e018910.","journal-title":"BMJ Open"},{"key":"1452_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.thromres.2021.09.012","volume":"213","author":"Y Ohashi","year":"2022","unstructured":"Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, et al. One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: results from the Cancer-VTE Registry. Thromb Res. 2022;213:203\u201313.","journal-title":"Thromb Res"},{"issue":"35","key":"1452_CR19","first-page":"33","volume":"2008","author":"S Tanaka","year":"2001","unstructured":"Tanaka S, Nishigami K, Taniguchi N, Matsuo H, Hirai T, Kaneda S, et al. Criteria for ultrasound diagnosis of deep venous thrombosis of lower extremities. J Med Ultrason. 2001;2008(35):33\u20136.","journal-title":"J Med Ultrason"},{"key":"1452_CR20","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s12185-008-0047-x","volume":"87","author":"H Nomura","year":"2008","unstructured":"Nomura H, Wada H, Mizuno T, Katayama N, Abe Y, Noda M, et al. Negative predictive value of D-dimer for diagnosis of venous thromboembolism. Int J Hematol. 2008;87:250\u20135.","journal-title":"Int J Hematol"},{"key":"1452_CR21","unstructured":"National Cancer Centre Japan. Cancer Statistics in Japan. 2015. http:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/short_pred_past\/ short_pred2015.html. Accessed 15 Sep 2022."},{"key":"1452_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12282-015-0599-6","volume":"22","author":"J Kurebayashi","year":"2015","unstructured":"Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, et al. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer. 2015;22:235\u201344.","journal-title":"Breast Cancer"},{"key":"1452_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458\u201364.","journal-title":"Arch Intern Med"},{"key":"1452_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07045-y","author":"ZA Razouki","year":"2022","unstructured":"Razouki ZA, Ali NT, Nguyen VQ, Escalante CP. Risk factors associated with venous thromboembolism in breast cancer: a narrative review. Support Care Cancer. 2022. https:\/\/doi.org\/10.1007\/s00520-022-07045-y.","journal-title":"Support Care Cancer"},{"key":"1452_CR25","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/SAP.0000000000001249","volume":"80","author":"A Momeni","year":"2018","unstructured":"Momeni A, Fox JP. Venous thromboembolism after surgical treatment of breast cancer. Ann Plast Surg. 2018;80:188\u201392.","journal-title":"Ann Plast Surg"},{"key":"1452_CR26","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.amjsurg.2016.09.038","volume":"212","author":"SG Zammar","year":"2016","unstructured":"Zammar SG, Pockaj BA, Stucky CC, Wasif N, Gray RJ. Is forgoing chemical venous thromboembolism prophylaxis for women undergoing breast-conserving surgery for breast cancer safe? Am J Surg. 2016;212:1162\u20136.","journal-title":"Am J Surg"},{"key":"1452_CR27","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/cancers14040988","volume":"14","author":"AP Londero","year":"2022","unstructured":"Londero AP, Bertozzi S, Cedolini C, Neri S, Bulfoni M, Orsaria M, et al. Incidence and risk factors for venous thromboembolism in female patients undergoing breast surgery. Cancers (Basel). 2022;14:988.","journal-title":"Cancers (Basel)"},{"key":"1452_CR28","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484\u20138.","journal-title":"Blood"},{"key":"1452_CR29","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1253\/circj.CJ-17-0445","volume":"81","author":"Y Yamashita","year":"2017","unstructured":"Yamashita Y, Shiomi H, Morimoto T, Yoneda T, Yamada C, Makiyama T, et al. Asymptomatic lower extremity deep vein thrombosis: clinical characteristics, management strategies, and long-term outcomes. Circ J. 2017;81:1936\u201344.","journal-title":"Circ J"},{"key":"1452_CR30","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0049-3848(11)00006-5","volume":"127","author":"J Trujillo-Santos","year":"2011","unstructured":"Trujillo-Santos J, Casas JM, Casado I, Samperiz AL, Quintavalla R, Sahuquillo JC, et al. Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Thromb Res. 2011;127:S1-4 (Erratum in: Thromb Res 2011;128:e1).","journal-title":"Thromb Res"},{"key":"1452_CR31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10549-018-05086-8","volume":"174","author":"X Xu","year":"2019","unstructured":"Xu X, Chlebowski RT, Shi J, Barac A, Haque R. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. Breast Cancer Res Treat. 2019;174:785\u201394.","journal-title":"Breast Cancer Res Treat"},{"key":"1452_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/MBC.0000000000001043","volume":"32","author":"AS Faiz","year":"2021","unstructured":"Faiz AS, Guo S, Kaveney A, Philipp CS. Risk of venous thromboembolism and endocrine therapy in older women with breast cancer in the United States. Blood Coagul Fibrinolysis. 2021;32:373\u201381.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1452_CR33","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/bloodadvances.2021006623","volume":"6","author":"M Blondon","year":"2022","unstructured":"Blondon M, Bodmer A, Thouvenin L, Lecompte T, Righini M, Fontana P, et al. Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort. Blood Adv. 2022;6:2884\u201392.","journal-title":"Blood Adv"},{"key":"1452_CR34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/cncr.20347","volume":"101","author":"SR Deitcher","year":"2004","unstructured":"Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004;101:439\u201349.","journal-title":"Cancer"},{"key":"1452_CR35","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1200\/JCO.1996.14.10.2731","volume":"14","author":"KI Pritchard","year":"1996","unstructured":"Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol. 1996;14:2731\u20137.","journal-title":"J Clin Oncol"},{"key":"1452_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.thromres.2021.11.009","volume":"208","author":"E Bolzacchini","year":"2021","unstructured":"Bolzacchini E, Pomero F, Fazio M, Civitelli C, Fabro G, Pellegrino D, et al. Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4\/6 inhibitors: a systematic review and meta-analysis. Thromb Res. 2021;208:190\u20137.","journal-title":"Thromb Res"},{"key":"1452_CR37","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s12282-020-01139-3","volume":"5","author":"N Hayashi","year":"2020","unstructured":"Hayashi N, Kumamaru H, Isozumi U, Aogi K, Asaga S, Iijima K, et al. Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer. 2020;5:803\u20139.","journal-title":"Breast Cancer"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-023-01452-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-023-01452-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-023-01452-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T15:19:09Z","timestamp":1687360749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-023-01452-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1452"],"URL":"https:\/\/doi.org\/10.1007\/s12282-023-01452-7","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"29 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shozo Ohsumi had no conflicts of interest to be disclosed. Kenichi Watanabe received lecture fees from Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Kyowa Kirin Co., Ltd., Novartis Pharma K.K., Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Pfizer Japan Inc., and Shionogi & Co., Ltd., outside the submitted work. Naoto Kondo had no conflicts of interest to be disclosed. Yoshimasa Kosaka received lecture fees from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AstraZeneca K.K., Novartis Pharma K.K., Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Nippon Kayaku Co., Ltd., and received support for attending meetings from Nippon Kayaku Co., Ltd., outside the submitted work. Takashi Ishikawa received lecture fees from AstraZeneca K.K., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., and Takeda Pharmaceutical Co., Ltd., and received research grants from Taiho Pharmaceutical Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Nippon Kayaku Co., Ltd., and Takeda Pharmaceutical Co., Ltd., outside the submitted work. Miyuki Kitahara had no conflicts of interest to be disclosed. Shinichiro Kubo had no conflicts of interest to be disclosed. Mari S Oba received lecture fees from SAS Institute Inc., EP SOGO Co., Ltd., Pfizer Japan Inc., and AstraZeneca K.K., outside the submitted work. Tetsuya Kimura and Atsushi Takita are employees of Daiichi Sankyo Co., Ltd. Hirofumi Mukai received consulting fees from Daiichi Sankyo Co., Ltd., as the submitted work, and received lecture fees from Taiho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., as the outside submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}